Table I.
Association between STCAT16 expression and clinical characteristics.
| STCAT16 | ||||
|---|---|---|---|---|
| Clinical characteristics | n | High (n=35) | Low (n=24) | P-value |
| Age (years) | 0.598 | |||
| <60 | 27 | 15 | 12 | |
| ≥60 | 32 | 20 | 12 | |
| Sex | 0.504 | |||
| Male | 35 | 22 | 13 | |
| Female | 24 | 13 | 11 | |
| Tumour size (cm) | 0.679 | |||
| <5 | 40 | 23 | 17 | |
| ≥5 | 19 | 12 | 7 | |
| Tumour, node and metastasis stage | 0.027a | |||
| I/II | 20 | 16 | 4 | |
| III/IV | 39 | 19 | 20 | |
| Differentiation degree | 0.400 | |||
| High or medium | 26 | 17 | 9 | |
| Low | 33 | 18 | 15 | |
| Lymph node metastasis | 0.025a | |||
| Yes | 34 | 16 | 18 | |
| No | 25 | 19 | 6 | |
a
P<0.05. If the expression level of STCAT16 in the tumour tissue was decreased >2 fold compared with the matched adjacent normal tissue, the expression level of STCAT16 was considered as low. STCAT16, stomach cancer-associated transcript 16.